文献速递免疫规划妇幼与学校卫生

既往感染SARS-CoV-2的5-11岁儿童对mRNA疫苗产生更强且持久的免疫应答

Stronger and durable SARS-CoV-2 immune response to mRNA vaccines in 5-11 years old children with prior COVID-19.
PubMed 文献 · Vaccine · 2023-12-08

这项多中心前瞻性观察研究在意大利两家医院纳入60名5-11岁儿童,其中46名既往SARS-CoV-2感染、14名未感染,接种BNT162b2疫苗后1个月和6个月检测抗体与免疫细胞。既往感染儿童抗S-RBD IgG及野生型、Omicron BA.2中和抗体滴度均高于未感染儿童,两组抗体从1个月到6个月下降约100%至250%。实体器官移植受者中和抗体和抗S-RBD IgG水平较低。

要点

  • 既往感染儿童接种后1个月和6个月抗S-RBD IgG及野生型、Omicron BA.2中和抗体滴度均高于未感染儿童。
  • 两组儿童抗体滴度从接种后1个月到6个月下降约100%至250%。
  • 实体器官移植受者中和抗体、抗S-RBD IgG及Tregs和Bregs频率均较低。

核心结论

  • 既往SARS-CoV-2感染的儿童接种mRNA疫苗后,至接种后6个月产生更高的特异性抗SARS-CoV-2抗体及调节性细胞水平。

研究设计与样本

  • 多中心前瞻性观察研究,2021年12月至2023年2月在意大利帕多瓦大学儿科医院和罗马Bambino-Gesù医院纳入60名5-11岁儿童,其中46名实验室确诊既往COVID-19、14名疫苗接种前无抗原特异性抗体(未感染)。
  • 于疫苗接种前、接种后1个月和6个月采集血样,用蚀斑减少中和试验(PRNT)检测中和抗体(NAbs)、化学发光免疫酶法(CLIA)检测抗刺突受体结合域(anti-S-RBD)IgG,流式细胞术分析免疫细胞表型。

主要发现

  • 60名儿童中26名(43%)为女性,中位年龄8岁(IQR=7-10.7)。
  • 既往感染儿童在接种后1个月和6个月抗S-RBD IgG及野生型和Omicron BA.2中和抗体滴度均高于未感染儿童。
  • 既往感染儿童抗体滴度与T调节细胞(Tregs)和B调节细胞(Bregs)频率相关。
  • 既往感染和未感染儿童从接种后1个月到6个月抗体滴度均下降约100%至250%。
  • 有免疫抑制基础疾病的儿童免疫应答与健康儿童相当,而实体器官移植受者中和抗体和抗S-RBD IgG水平较低,Tregs和Bregs频率也降低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: mRNA vaccines elicit a durable humoral response to SARS-CoV-2 in adults, whereas evidence in children is scarce. This study aimed to assess the early and long-term immune response to the mRNA vaccine in children with or without previous SARS-CoV-2 infection. METHODS: In a multicentre prospective observational study, we profiled the immune response to the Pfizer BioNTech (BNT162b2) vaccine in 5-11-year-old children attending the University Pediatric Hospital of Padua and Bambino-Gesù Hospital in Rome (Italy) from December-2021 to February-2023. Blood samples were collected pre-, 1-, and 6-months after vaccination. Neutralizing antibodies (NAbs) and anti-spike-receptor-binding-domain (anti-S-RBD) IgG titers were analyzed through Plaque Reduction Neutralization Test (PRNT) and chemiluminescent immune-enzymatic assay (CLIA), respectively. Immune cell phenotypes were analyzed by flow cytometry. RESULTS: Sixty children (26 [43 %] female, median age = 8 years [IQR = 7-10.7]) were enrolled in the study, including 46 children with a laboratory-confirmed previous COVID-19 (SARS-CoV-2-recovered) and 14 SARS-CoV-2-naïve participants defined as the absence of antigen-specific antibodies before vaccination. SARS-CoV-2-recovered participants recorded higher anti-S-RBD IgG and Wild-type and Omicron BA.2 NAbs titers than SARS-CoV-2-naïve participants at both 1- and 6-months after vaccination. Antibody titers correlated with T (Tregs) and B (Bregs) regulatory cell frequencies in SARS-CoV-2-recovered children. Both SARS-CoV-2-recovered and SARS-CoV-2-naïve participants decreased antibody titers by approximately 100 to 250 % from 1 to 6 months. While children with immunocompromising underlying conditions developed immune responses comparable to those of healthy children, solid organ transplant recipients exhibited lower levels of NAbs and anti-S-RBD IgG titers, as well as reduced frequencies of Tregs and Bregs. CONCLUSIONS: mRNA vaccination triggered a higher production of specific anti-SARS-CoV-2 antibodies along with increased levels of regulatory cells in children with previous SARS-CoV-2 infection up to the following 6 months. These findings provide insights into boosting pre-existing immunity.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Di Chiara C, Cantarutti A, Raffaella Petrara M, et al. Stronger and durable SARS-CoV-2 immune response to mRNA vaccines in 5-11 years old children with prior COVID-19. Vaccine. 2023. PMID: 38071105. doi:10.1016/j.vaccine.2023.12.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。